Publication: Analysis Of The Impact Of Genetic Evidence Derived From Whole Exome Sequencing On The Probability Of Drug Approval
No Thumbnail Available
Open/View Files
Date
2021-05-12
Authors
Published Version
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Giagtzoglou, Nikolaos. 2021. Analysis Of The Impact Of Genetic Evidence Derived From Whole Exome Sequencing On The Probability Of Drug Approval. Master's thesis, Harvard University Division of Continuing Education.
Research Data
Abstract
The rate of success in drug development is approximately 10%, which is
surprising low given the technological and conceptual advances in the fields of medicine
and biology. To increase the rate of success the right drug targets for the right indications
must be selected. Genetics and genomics can contribute significantly to this process.
However, thus far, the only sources of genetic evidence that have been considered are
either Genome Wide Association Studies (GWAS) or the Online Mendelian Inheritance
in Man (OMIM), which is an online catalog human genes and genetic disorders. In the
present study, we evaluated the impact of genetic information that has been derived from
whole exome sequencing (WES) upon the process of drug development. We discovered
that even WES signals detected at subthreshold statistical significance have positive
predictive value on the successful outcome of drug development.
Description
Other Available Sources
Keywords
drug approval, genome wide association studies, Online Mendelian Inheritance in Man, whole exome sequencing, Bioinformatics
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service